permanent neuropsychological impairment
recurrent episodes of severe hypoglycemia
retrospective study
selected patients with insulin-treated diabetes mellitus
only reliable predictors of severe hypoglycemia
history of hypoglycemia
history of hypoglycemia-related injury
convulsion
duration of insulin therapy
history of hypoglycemia
insulin for years
years in the insulin-treated patients without a history of hypoglycemia
human insulin
hypoglycemic episodes
animal insulin
caution
switching from animal
pork
purified porcine insulin
biosynthetic human insulin
increased potency
bioavailability
endocrine side effects
hypoglycemia
serious side effect of insulin
occurring
type
type
diabetic patients
incidence
depending on the populations
types of insulin therapy
etc
counterregulatory endocrinologic responses
hypoglycemia
responses
patients
severe hypoglycemia
confusion
sweating
tachycardia
coma
seizures
cardiac arrhythmias
neurological deficits
death
blood
urine glucose monitoring
patients
risk of hypoglycemia
signs
symptoms of hypoglycemia
risk
developing hypoglycemia
patients
continuous infusion insulin therapy
association between insulin
dyslipidemia
being
ocular side effects
reports of bilateral presbyopia
blurry vision
beginning of therapy
changes in the osmotic equilibrium between the lens
ocular fluids
dermatologic side effects
lipohypertrophy
insulin
lipoatrophy
incidence of lipoatrophy
use of purer forms of pork insulin
biosynthetic human insulin
injection sites
proper hygiene
subcutaneous insulin injections
infection
hypersensitivity side effects
systemic reactions
reactions
becoming
patients
use of purer forms of pork insulin
biosynthetic human insulin
local reactions
erythema
swelling
heat
subcutaneous nodules
weeks of therapy
true allergy
insulin
sensitization
specific animal proteins in bovine
pure forms of porcine insulins
diabetic patient with true allergy
insulin
desensitization
desensitization kits
protocols
insulin manufacturers
immunologic analysis of anaphylaxis
insulin preparations in some cases
elevated serum levels of lge
lgg
protamine
regular insulin
immunologic side effects
formation of anti-insulin antibodies
animal insulin formulations
presence of these antibodies
elimination half-life of insulin
cardiovascular
side effects
hyperinsulinemia
high frequency
macrovascular diseases in patients with diabetes
experts
evaluating insulin as a possible atherogenic agent
controversy
study
role of hyperinsulinemia as the precursor of hypertension
other cardiovascular risk factors
persons with carbohydrate intolerance
hypertension
abnormalities in platelet function
clotting factors
fibrinolytic system
dyslipidemia
relationship between diabetes
insulin
disorders
investigation
insulin
pathogenesis of hypertension
stimulating
sympathetic nervous system
promoting
promoting renal sodium retention
stimulating
stimulating vascular smooth muscle hypertrophy
dyslipidemia
promoting
promoting hepatic synthesis
low density lipoproteins
vldls
insulin
heart rate in the absence of hypoglycemia
general
side effects
weight gain
presenting as edema
abrupt restoration of glucose control in a patient
control
weight gain
efficient use of calories during insulin therapy
suggesting
suggesting additional benefits of dietary
exercise modifications
patients on intensive insulin therapy
weight gain
intensive insulin therapy
increase in body fat as a result of the elimination of glycosuria
reduction
hour energy expenditure
reduction
h energy expenditure
result of an insulin-associated decrease in triglyceride/free fatty acid cycling
nonoxidative glucose
protein metabolism
rare cases of hypophosphatemia
use of glucose
insulin
potassium infusions during the treatment of myocardial infarction
metabolic side effects
reports of hypokalemia
hypomagnesemia
patients
being
diabetic ketoacidosis
dka
insulin
intracellular transport of phosphate
hypophosphatemia during treatment of dka
renal side effects
reports
decreased renal plasma flow
glomerular filtration rate
urinary albumin excretion rate from insulin-induced hypoglycemia
changes
resolution of hypoglycemia
hypoglycemia
increased plasma dopamine
epinephrine
plasma renin activity
acute changes in renal function during insulin-induced hypoglycemia
direct stimulation of the efferent sympathetic nerves
kidney
hormonal counterregulatory mechanisms
hematologic side effect
increase in the concentration of von willebrand factor
insulin-induced hypoglycemia
increased von willebrand factor
hypoglycemia-associated decreased plasma volume
increased plasma viscosity
patients
reduced peripheral perfusion
embolic phenomenon
single case of insulin-induced hemolytic anemia
effects of insulin-induced hypoglycemia on hemostasis
clinical observations of embolic phenomenon during treatment of diabetic ketoacidosis
limited data
diabetics
lower basal concentration of tissue plasminogen activator
gi distress
dose reduction